543434

- Supriya Lifescience intimated about judicial proceedings against Mr. Sreekant Sreedharan, General Manager, Sales & Marketing. - He is under judicial detention until July 17, 2026, following an investigation by the Customs Department under the NDPS Act for a procedural lapse. - The company states no material impact on operations, financial position, or governance is expected.

- Board recommended a final dividend of Re. 1.00 (50%) per equity share for FY 2025-26, subject to shareholder approval at the AGM. - Dividends are taxable in shareholders' hands, and the company will deduct TDS. - Shareholders need to submit tax-related documents by July 15, 2026, for appropriate TDS.

- Trading window closed from July 01, 2026, until 48 hours post-Q1 FY27 unaudited financial results declaration for the quarter ended June 30, 2026. - This is in compliance with SEBI Insider Trading Regulations.

- Concall Schedule - Concall Date: June 18, 2026 - Concall Time: 02:00 PM - 03:00 PM

New Filing detected. See link for details.

- Reiterated FY27 guidance of approximately 20% annual revenue growth and EBITDA margin of 33-35%. - On track to achieve INR 1,000 crores revenue milestone by FY27. - Lote facility received USFDA Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification, with only one minor observation. - Patalganga land clearances secured; Phase 1 groundbreaking in FY27 with planned capex of INR 200 crores for two API/intermediate and two formulation blocks. - Scheduled annual maintenance shutdown in Q2 FY27 (August) for older blocks A&D, impacting quarterly linearity of growth. - R&D investments doubled, focusing on new APIs, CMO/CDMO/CRO, and formulations R&D. - Ambernath facility expected to start revenue contribution in FY27, with EU audit scheduled for H2 FY27. Full impact expected in 3-4 years.

Supriya Lifescience Ltd. submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required by Regulation 24A of SEBI (LODR) Regulations, 2015. The report, issued by M/s. DSM & Associates, confirmed that the company fully complied with all applicable SEBI regulations and Secretarial Standards, with no non-compliances or deviations observed during the review period.

Supriya Lifescience Limited announced that the audio recording of its Earnings Call, held on May 28, 2026, discussing the operational and financial performance for the quarter and year ended March 31, 2026, is now available on the company's website.

Supriya Lifescience Limited reported Q4 FY26 consolidated results: Revenue ₹276.53Cr vs ₹184.11Cr (▲50.20% YoY), EBITDA ₹97.62Cr vs ₹67.58Cr (▲44.45% YoY), PAT ₹74.23Cr vs ₹50.37Cr (▲47.37% YoY). EBITDA Margin was 35.3% vs 36.7% (▼140bps). The company delivered strong performance with revenue growth driven by the anesthetic segment and improved capacity utilization.

Supriya Lifescience Ltd. reported Standalone Revenue of ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA of ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), and PAT of ₹74.23 Cr vs ₹50.38 Cr (▲47.36% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 35.30% vs 36.71% (▼141bps). The Board recommended a final dividend of ₹1.00 per equity share (50% on face value of ₹2/- each), subject to shareholder approval.

Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.44% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.35% YoY). EBITDA Margin 35.29% vs 36.71% (▼142 bps). The board also recommended a final dividend of Re. 1.00 per equity share for the financial year ended March 31, 2026.

Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.34% YoY). EBITDA Margin 35.29% vs 36.71% (▼142bps). The company also recommended a final dividend of Re. 1.00 per equity share.